27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
In a 24-week, randomized, double-blind, placebo-controlled, multicenter study of rivastigmine, 487 patients with dementia associated with Parkinson disease underwent assessment of attention on the Cognitive Drug Research computerized cognitive assessment system before dosing and 16 and 24 weeks later. 2 key findings →
Participants: 487 Evidence: high
Full summary, score breakdown and related studies → Original source
We examined whether cognitive function at baseline affected cognitive and cardiovascular outcomes in the Study on COgnition and Prognosis in the Elderly (SCOPE), a blood pressure (BP)-lowering intervention trial. 4 key findings →
Design: open-label trial Participants: 2,070 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This randomized, observer-blind, controlled trial examined the efficacy and safety of the traditional Chinese herbal medicine Yi-Gan San (YGS, Yokukan-San in Japanese) in the improvement of behavioral and psychological symptoms of dementia (BPSD) and activities of daily living (ADL). 4 key findings →
Participants: 27 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The Mini-Mental State Examination (MMSE) is recommended to test for cognitive impairment and to monitor medication response. 4 key findings →
Design: randomized controlled trial Participants: 7,073 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A total of 533 patients with AD at early stages (mean Folstein Mini-Mental State Examination [MMSE] 21/30 at entry) were recruited and followed semiannually for up to 13.1 years (mean 3) in five University-based AD centers in the United States and European Union. 4 key findings →
Participants: 533 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cognitive functions and self-reported drinking habits were assessed at 2-year intervals over an average of 7 years of follow-up. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
CERAD total scores were obtained by summing scores from the individual CERAD subtests (excluding the Mini-Mental State Examination [MMSE]) into a total composite (maximum score = 100). 4 key findings →
Participants: 424 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
According to all previous literature, they are not associated with mortality. 4 key findings →
Participants: 456 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Despite advances in the clinical characterization of FTD, little is known about its rate of progression. 4 key findings →
Participants: 70 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The authors reviewed 135 subjects from a community-based study of dementia for whom autopsy and brain tissue was available. 4 key findings →
Participants: 135 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Quality of life (QoL) is becoming an increasingly used outcome measure in both clinical practice and research but little is known about QoL in dementia and how it may change over time. 4 key findings →
Design: longitudinal study Participants: 60 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
While the Mini-Mental State Examination (MMSE) was originally developed to screen for dementia and delirium, many neurologists use this measure as a screening instrument for 'cognitive impairment' in hospitalized stroke patients. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
From a prospective Memory Clinic cohort including consecutively referred patients, age 60 years or above, and with MMSE score 20 or above, 36 patients with AD and 30 with MCI were included in this study. 4 key findings →
Participants: 36 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We investigated consecutive patients with dementia. 4 key findings →
Participants: 536 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The validity of a new computerised battery called CogState was determined in 60 individuals with advanced human immunodeficiency virus-1 (HIV-1) infection from which eleven were assessed as AIDS dementia complex (ADC) stage 1 or 2. 1 key finding →
Participants: 60 Evidence: low
Full summary, score breakdown and related studies → Original source
Cholinergic neuron loss is a cardinal feature of Alzheimer disease. 1 key finding →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is characterized by cognitive decline and loss of neurons in specific brain regions. 4 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Health-related quality of life (HR-QOL) scales are particularly important in older people as global outcome measures for interventions. 4 key findings →
Participants: 79 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Mild cognitive impairment (MCI) has been considered a transitional state between normal aging and dementia, characterised by memory impairment but normal general cognitive functioning. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The prevalence of comorbidities and functional impairment among elderly patients may enhance the risk of operation-related complications, but the importance of these conditions in elderly patients undergoing thoracic surgery remains unclear. 4 key findings →
Participants: 120 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The burden perceived by caregivers of patients with dementia is a fundamental prognostic aspect in the history of the disease. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Depression is a frequent condition in Alzheimer's disease (AD). 4 key findings →
Participants: 316 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Showa University Karasuyama Hospital, Tokyo, Japan. 4 key findings →
Participants: 106 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Neuropsychiatric symptoms seen in Alzheimer's disease (AD) are not simply a consequence of neurodegeneration, but probably result from differential neurotransmitter alterations, which some patients are more at risk of than others. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The increased tendency to fall asleep during the daytime together with increased wakefulness during the night has been demonstrated in patients with advanced Alzheimer's disease (AD). 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →